Improved QoL seen with both stimulant and nonstimulant medications
THURSDAY, Aug. 15, 2024 (HealthDay News) — Medications for attention-deficit/hyperactivity disorder (ADHD) are effective at improving quality of life in people with the disorder, according to a review recently published in the Journal of the American Academy of Child & Adolescent Psychiatry.
Alessio Bellato, Ph.D., from the University of Southampton in the United Kingdom, and colleagues conducted a systematic review and meta-analysis to quantify the effect of ADHD medication on quality of life.
Based on 17 randomized controlled trials (5,388 participants), the researchers found that amphetamines (Hedge”s g = 0.51), methylphenidate (Hedge”s g = 0.38), and atomoxetine (Hedge”s g = 0.30) were significantly more efficacious than placebo in improving quality of life in people with ADHD, with moderate effect size. These effects were not moderated by the length of intervention for atomoxetine, and did not differ between children/adolescents and adults.
“It could be that reducing the core symptoms of ADHD (inattention, hyperactivity, impulsivity) leads to more efficient task management and this results in better academic and professional outcomes,” Bellato said in statement. “Medications may also help to stabilize emotional dysregulation, which might promote emotional well-being and higher self-esteem.”
One author disclosed ties to the pharmaceutical industry.
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria